Reading glasses could soon be a thing of the past thanks to a new eye drop solution that can help treat far-sightedness.

Earlier this month, Israeli-based Orasis Pharmaceuticals announced that its CSF-1 corrective eye drop successfully met the primary endpoint in a Phase 2b clinical study in temporarily reversing presbyopia, a very common condition that gradually causes far-sightedness in older adults.

According to the company, CSF-1 successfully demonstrated statistically significant improvement in distance-correction. Not only that, the drops also demonstrated an exceptional safety and tolerability profile.

"The successful completion of the Phase 2b study is a significant milestone for Orasis. We are encouraged by these results and CSF-1's potential to improve the quality of life for people with presbyopia," said Orasis CEO Elad Kedar. "CSF-1 can potentially alleviate the burden of reading glasses and offer a meaningful solution for billions of people living with age-related farsightedness worldwide."